Stock ABVX ABIVAX
Add to a list
To use this feature you must be a member
Log inSign up

Financials Abivax

Equities

ABVX

FR0012333284

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 11:35:09 2024-05-10 am EDT 		5-day change 1st Jan Change
13.38 EUR -0.59% Intraday chart for Abivax -4.84% +36.25%
May. 08 Abivax: four abstracts to be presented on obefazimod CF
May. 08 Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 265.2 475.9 467.2 103.7 615.2 841.8 - -
Enterprise Value (EV) 1 276.6 446.6 406.5 76.71 439.9 754.4 797.2 566.9
P/E ratio -8.98 x -13.1 x -11.6 x -1.97 x -2.86 x -4.85 x -4.73 x -4.05 x
Yield - - - - - - - -
Capitalization / Revenue - 280 x 48.2 x 1,037 x 134 x 255 x 391 x 109 x
EV / Revenue - 263 x 41.9 x 767 x 95.6 x 229 x 370 x 73.6 x
EV / EBITDA -8.33 x -11.8 x -9.59 x -1.36 x -3.47 x -5.11 x -4.76 x -3.04 x
EV / FCF -9.74 x -14.5 x -8.59 x -1.16 x -4.52 x -5.4 x -5.11 x -3.89 x
FCF Yield -10.3% -6.88% -11.6% -85.9% -22.1% -18.5% -19.6% -25.7%
Price to Book - - 13.4 x 15.8 x 3.15 x 8.31 x -13.5 x -
Nbr of stocks (in thousands) 11,762 13,834 16,363 16,774 62,646 62,918 - -
Reference price 2 22.55 34.40 28.55 6.180 9.820 13.38 13.38 13.38
Announcement Date 3/16/20 3/31/21 3/16/22 4/19/23 4/2/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 1.7 9.7 0.1 4.6 3.297 2.152 7.708
EBITDA 1 -33.22 -37.94 -42.4 -56.57 -126.7 -147.7 -167.3 -186.7
EBIT 1 -33.3 -38 -42.6 -56.6 -127.4 -152.6 -177.3 -215.6
Operating Margin - -2,235.29% -439.18% -56,600% -2,769.57% -4,629.66% -8,237.33% -2,796.76%
Earnings before Tax (EBT) 1 -34.9 -40.1 -45.6 -74.32 -147.7 -155.8 -177 -209.6
Net income 1 -30.6 -37.6 -41.4 -69.8 -147.4 -159.2 -173.3 -224
Net margin - -2,211.76% -426.8% -69,800% -3,204.35% -4,828.97% -8,053.28% -2,905.73%
EPS 2 -2.510 -2.620 -2.470 -3.130 -3.430 -2.757 -2.827 -3.300
Free Cash Flow 1 -28.41 -30.72 -47.3 -65.88 -97.4 -139.7 -156 -145.6
FCF margin - -1,807.12% -487.62% -65,885% -2,117.28% -4,237.01% -7,245.3% -1,889.02%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/16/20 3/31/21 3/16/22 4/19/23 4/2/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 S1 2023 S1 2023 S2 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2 2025 Q1
Net sales 1 - - 2.4 1.123 1.123 2.35 1.123 1.123 2.35 1.123
EBITDA - - - - - - - - - -
EBIT 1 -18.6 - - -32.13 -32.13 -95.6 -32.13 -32.13 -103.6 -32.39
Operating Margin - - - -2,861.44% -2,861.44% -4,068.09% -2,861.44% -2,861.44% -4,408.51% -2,884.59%
Earnings before Tax (EBT) 1 - - - -32.13 -32.13 -101.6 -32.13 -32.13 -109.6 -32.39
Net income 1 -29.6 -51.95 -95.4 -32.13 -32.13 -97.45 -32.13 -32.13 -105.6 -32.39
Net margin - - -3,975% -2,861.44% -2,861.44% -4,146.81% -2,861.44% -2,861.44% -4,493.62% -2,884.59%
EPS - -1.450 - - - -1.620 - - -1.540 -
Dividend per Share - - - - - - - - - -
Announcement Date 9/15/22 9/29/23 4/2/24 - - - - - - -
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 11.4 - - - - - - -
Net Cash position 1 - 29.3 60.7 27 175 87.4 44.7 275
Leverage (Debt/EBITDA) -0.3432 x - - - - - - -
Free Cash Flow 1 -28.4 -30.7 -47.3 -65.9 -97.4 -140 -156 -146
ROE (net income / shareholders' equity) - - - - -145% -131% -202% -122%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - - 2.130 0.3900 3.120 1.610 -0.9900 -
Cash Flow per Share 2 -2.400 -2.170 -2.820 -2.940 - -2.200 -2.100 -
Capex 1 0.94 0.9 1.64 0.31 0.27 2.1 2 6
Capex / Sales - 52.82% 16.93% 306% 5.76% 63.7% 92.92% 77.84%
Announcement Date 3/16/20 3/31/21 3/16/22 4/19/23 4/2/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Abivax

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
13.38 EUR
Average target price
37.59 EUR
Spread / Average Target
+180.94%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ABIVAX Stock Abivax
+36.25% 912M
MODERNA, INC. Stock Moderna, Inc.
+17.96% 47.02B
LONZA GROUP AG Stock Lonza Group AG
+48.77% 41.86B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.17% 41.76B
CELLTRION, INC. Stock Celltrion, Inc.
-4.27% 28.8B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.42% 26.05B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.39% 19.15B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.86% 12.55B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.29% 12.34B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.50% 11.82B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ABVX Stock
  4. Financials Abivax
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW